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Abstract
Background—Alström syndrome (ALMS) is a rare autosomal recessive monogenic disease
associated with obesity, hyperinsulinemia and alterations of glucose metabolism that often lead to
the development of type 2 diabetes in a young age.
Objective—Relationship between weight and metabolism has been studied in a group of ALMS
patients and matched controls.
Research design and methods—Fifteen ALMS patients (8 M, 7 F, aged 3-51 yrs) were
compared in a cross-sectional study with an age- and weight-matched control population.
Anthropometric parameters, fat mass, glucose and insulin secretion in basal and dynamic (OGTT)
conditions were measured. Further anthropometric and body composition data were obtained from
an International group of 27 ALMS patients (13 M, 14 F, age range: 4-29 yrs).
Results—In ALMS we observed an inverse correlation between age and SDS for height, weight
and BMI. The OGTT glycemic curves of ALMS subjects were similar to those of age-matched
controls, while insulin response was clearly greater. In ALMS individuals the insulin response
showed a reduction with age. We documented pathologic values of the derived indices HOMA-IR,
ISI, HOMA%β cell and Insulinogenic Index in ALMS, but unlike the insulin-resistance indices,
the beta-cell function indices showed a significant reduction with age.
Conclusions—In ALMS the progression from the early onset obesity towards the impaired
fasting glucose or IGT and overt diabetes is mostly due to a progressive failure of β-cell insulin
secretion without any further worsening of insulin resistance with age, even in the presence of
weight reduction.
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Introduction
Alström syndrome (ALMS) (OMIM 203800) is a recessive monogenic disease, affecting
multiple organ systems, and caused by mutations in ALMS1, a large gene on chromosome
2p13 [1]. Approximately 700 patients have been diagnosed world-wide so far [personal
communication-jdm]. The role of the ALMS1 protein is not yet known, although it localizes
to the basal bodies of centrosomes and is implicated in ciliary function [2]. ALMS is
characterized by a progressive retinal cone-rod dystrophy causing nystagmus and
photodysphoria in the first months of life, and leading to blindness by adulthood [3,4]. A
mild-to-profound bilateral sensorineural hearing loss develops throughout childhood.
Dilated cardiomyopathy is reported in 60% of cases and can occur at various stages of life,
primarily infancy [5]. Patients in adolescence or adulthood often present with progressive
restrictive cardiomyopathy. They also exhibit variable urologic and pulmonary disturbances.
Progressive hepatic and renal failure occur as the ALMS patient ages. The life span of
ALMS individuals rarely exceeds 40 years if cardiac involvement is severe [1]. Systemic
fibrosis has been found in biopsy and post-mortem specimens, and probably contributes to
systemic complications and multi-organ failure [1,5].
Most children with ALMS are obese, with marked hyperinsulinaemia associated with
acanthosis nigricans. Type 2 diabetes mellitus (T2DM) develops in 70% of subjects in the
2nd-3rd decade of life [1,5]. Other common metabolic disorders in adolescents and adults
include hypertriglicerydaemia, hyperuricaemia and a non alcoholic steatohepatitis associated
with liver function abnormalities. Endocrinological problems have been reported including
hypothyroidism, GH-deficiency, primary hypogonadism in males and hyperandrogenism in
females [1,5,6].
The mechanisms underlying the development of hyperinsulinemia and T2DM are still
unknown in ALMS. Whether metabolic complications are primarily related to genetic
determinants or body weight is still a matter of discussion. Furthermore, it has not been
clarified whether T2DM in ALMS is attributed principally to decreased insulin-stimulated
glucose uptake, progressive beta-cell failure, or both.
The aim of this study has been to specifically address the time course of insulin-resistance
and beta-cell function, in relation to age, weight variations and body composition in a group
of paediatric and adult patients affected by Alström syndrome.
Methods
Italian patients
Fifteen patients were included in this cross-sectional study (8 males and 7 females) and all
satisfied the clinical and genetic criteria for the diagnosis of Alström syndrome [1] (Table
1). A 2-yr-old ALMS female was excluded from the study due to her “outlier phenotype” of
low weight (BMI 13.43) associated with feeding disorders and neurological development
delay.
The age range was 3-51 years (y), with a median age of 23,8 y; comprising six paediatric
patients (3-13 y). There were 4 sets of siblings (# 2,4; 8,10; 9,12; 14,15) (Table 1). One
patient (# 13) was born from a first-degree consanguineous union. Patients # 6 and # 10 are
deceased at age 13 and 29 respectively. Although the patients came from various regions of
Italy, they were all followed in our department, with the exception of patient # 10 who was
diagnosed retrospectively by clinical records and genetic confirmation of archived DNA
samples. Careful medical history, clinical examinations, anthropometric measurements
(weight, height, body mass index, waist circumference), metabolic and endocrinological
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assessments were obtained from each patient. 8 of the living adult patients were also
evaluated for body composition (fat mass) by bioelectrical impedance analysis (BIA).
Medical information from multiple yearly evaluations was collected from previous clinical
records. For metabolic investigations, patients were divided into 3 groups according to age,
as shown in table 2.
Patients were also investigated for the following hormones: FT3, FT4, TSH, LH, FSH, 17β-
estradiol, progesterone, PRL, testosterone, cortisol, ACTH, GH (basal and after stimulation
with GHRH+arginine), and IGF-I. Based on these results, we found 4 patients with
hypothyroidism, 3 with hypogonadism and 4 had GH-deficiency. Finally patients underwent
the following investigations: electrocardiography, echocardiography, chest X-ray,
abdominal US examination, and audiometry.
Control subjects
A group of 36 control subjects (age range 3-44 y), was evaluated in the following
proportion: 5 subjects <7 y, 10 subjects 7-18 y, 21 subjects >18 y. This control population
was selected from patients referred to our department for weight disorders excluding the
presence of a monogenic obesity. BMI in the control group was not significantly different
from that of ALMS subjects (ALMS vs Controls respectively: < 7 years 25,4 vs 25,1; 7-18
years 28,1 vs 31,9; >18 years 28,0 vs 27,2). Three control subjects presented impaired
fasting glycaemia. Additionally, the waist circumference in the adult patients (age > 18 y)
was not significantly different between the two groups.
International group of ALMS patients
Body composition data were derived from BIA analysis of an additional group of 27 ALMS
subjects (13 males, 14 females, age range: 4-29 y) examined during an Alström Syndrome
International Meeting (Ontario, Canada 2001). Combining the data from the Italian and
International groups of patients, we calculated the Standard Deviation Scores (SDS) for
weight, height and BMI of all the measurements in our possession, performed in patients
under 24 y.
Assays—We investigated Italian ALMS patients and control subjects for the following
analyses, according to the standard laboratory methods of the central laboratory of Padua
University Hospital. All the fasting venous blood samples were obtained from 7.30-9.30
AM. The measurements taken and their normal range (enclosed in parenthesis) are the
following:
Basal investigations: Glucose [3,7-6,1 mmol/L]; Insulin [6,0-29,1 mmol/L]; AST [10-45 U/
L]; ALT [10-50 U/L]; γGT [3-65 U/L]; Total Cholesterol [desirable <5,18 mmol/L, elevated
>6,19 mmol/L]; LDL cholesterol [desirable <3,36 mmol/L, elevated >4,11 mmol/L]; HDL
cholesterol [desirable >1,00 mmol/L; protective >1,55 mmol/L]; Triglycerides [desirable
<1,69 mmol/L]; ApoA1 [1,15-2,20 g/L]; ApoB [0,70-1,60 g/L].
Dynamic investigations: In non-diabetic ALMS patients an OGTT with ingestion of 75 g of
glucose dissolved in 200 ml water flavoured with citric acid was performed according to
WHO standards, including an FBG and a blood glucose measurement after 30, 60, 90, 120
and 180 minutes. The dose of glucose load in the paediatric population was 1.75 grams of
glucose per kilogram of body weight to a maximum dose of 75 g (age < 7y OGTT
measurements after 30, 60, 120 m′)
Derived measurements: In order to investigate fasting insulin-resistance and fasting beta-
cell function, we used the homeostatic model HOMA1 (Homeostasis Model Assessment) [8]
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which requires the parameters of fasting glucose and insulin calculated according to the
following formula: HOMA insulin-resistance (HOMA1-IR)=
The formula used to obtain basal beta-cell function (HOMA1 %β cell) is the following:
Matsuda index [9], also called Insulin Sensitivity Index (ISI), was utilized to estimate insulin
sensitivity during OGTT:
where G0 and I0 indicate fasting glucose and fasting insulin, respectively, and Gm and Im
correspond to the mean of glucose and insulin during OGTT (0′-180′).
The last index, the Insulinogenic Index [10], estimates the early phase insulin secretion, and
was calculated as the ratio of the increment of serum insulin 30 minutes after an oral glucose
load, to blood glucose concentration 30 minutes after the glucose load:
Body composition measurements: Weight was measured in light indoor clothing to the
nearest 0,1kg, and height measured without shoes to the nearest 0,1 cm using a portable
stadiometer. BMI was calculated as weight (kg) / height (m)2. For adult patients (≥ 18
years), overweight and obesity were classified according to the WHO guidelines (1997),
which define overweight as a BMI ≥ 25 and < 30, and obesity as a BMI ≥ 30. The
classifications of overweight and obesity in paediatric patients were defined by Cole et al
[11]. The SDS of BMI, weight and height were obtained using a web calculation tool
(http://www.phsim.man.ac.uk/ SDSCalculator; SDS Individual Calculator for British 1990
Growth Reference Data). Waist circumferences were measured to the nearest 0,1 cm using a
flexible non-stretchable tape measure. BIA measurements were taken in fasting condition, in
a supine position and at rest. We utilized the bioelectric impedance analyzer, STA-BIA
Body Composition Analyzer (Akern Bioresearch, Florence, Italy), and the data were
elaborated by the software BIA-SITA and Bodygram software (Akern Bioresearch,
Florence, Italy). Fat free mass (FFM) was expressed by percentage of total body weight
(%FFM), and the fat mass (FM) was calculated as the difference between total body weight
and the FFM, and it was also expressed as a percentage of total body weight (%FM). Both
Italian and International group of patients were evaluated using the same impedentiometer.
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Statistical analyses—Results are expressed as mean ± standard error of the mean (SEM).
Comparisons between ALMS and control patients were calculated using the unpaired t-test
(with correction for multiple measurements)..Correlations between normally distributed
continuous variables were analysed by least mean squares regressions. p<0,05 was
considered significant.
Results
Body composition measurements
Anthropometric variables of 9 adult Italian patients (Table 1) showed that 1 had a normal
body weight, 7 were overweight and 1 was obese. Among the 6 paediatric patients (Table 1),
1 was overweight and 5 were obese. Retrospectively, 7 adult patients were found to be obese
in their infancy. Considering the stature trend in terms of SDS from 39 patients (13 Italian
and 26 International), we found that there was an inverse correlation with age (r= -0,554;
p=0,0001). In infancy, stature-SDS values were markedly positive, while in adulthood they
were negative (higher stature-SDS +3,86 at 8 y, lower stature-SDS -2,97 at 21 y). Also body
weight-SDS, in the same group of patients, was found to have an inverse correlation with
age (r=-0,43; p=0,001) and it was always positive. We also found an inverse correlation of
BMI-SDS with age (r= -0,36; p= 0,006). When analyzed separately by gender, there were no
correlations between age and anthropometric parameters in females, with the exception of
height-SDS (Table 3). BIA data from 32 ALMS patients (8 Italian and 24 International; age
range 5-51 y) showed that only in males there was a significant reduction of FM% and an
increasing of FFM% with age (Table 3).
Metabolic characteristics
We found that, in the group of age < 7y, all (5/5) had normal glucose tolerance, in the 7-18 y
group 3 patients out of 5 had normal glucose tolerance and 2 had IGT. Finally, in the >18
years group, 3 patients out of 9 had normal glucose tolerance, 4 had IGT and 2 were diabetic
(Table 1 and 2). Basal insulin was elevated in all patients belonging to the two older patient
groups (7- 18y and >18 y), with the exception of 4 patients (#9,12,14,15).
We compared glucose and insulin response during OGTT in ALMS and control patients (Fig
1). Glycemic curves including glycaemia-AUC, were largely indistinguishable from each
other in all age groups. On the contrary, insulin curves (age > 7y) differ significantly
between ALMS and control patients. There was a higher insulin-AUC in ALMS compared
to controls in both older groups (Fig 1). We also compared the derived indices, of insulin
resistance and beta cell function, in ALMS and controls in different age groups (Fig 2) and
found that in both the 7-18y and > 18y age groups, HOMA-IR, HOMA%βcell and
Insulinogenic Index were higher in ALMS than in controls. ISI was higher in controls only
in the age group >18y. Finally, both HOMA%βcell and Insulinogenic Index decreased with
age in ALMS individuals. There were no gender differences in insulin sensitivity nor in
insulin resistance.
Lipids, Uric acid and Hepatic enzymes
Triglycerides were remarkably elevated in all patients over 7 y, except in one case (patient
#7). One patient (#9) presented with hypertriglyceridaemia at 1 year of age. Eight adult
patients out of 9 (88%) had dyslipidemia, while among pediatric patients a mild
dyslipidemia was observed in 3 patients out of 6. We found low levels of apolipoproteinA1
and high levels of uric acid (> 0,42 mmol/L) in 6 adult patients. On evaluations of hepatic
enzymes, we found that ALT and gGT in particular, tended to rise over the life of these
patients (Fig 3).
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Discussion
Alström syndrome is very rare, with approximately 700 cases having been identified since
first described in 1959 [12]. Obesity, insulin resistance and T2DM are among the major
criteria for the diagnosis of Alström syndrome, both in pediatric and adult populations. This
study shows that development of insulin resistance and beta cell failure in Alström
syndrome are distinct in mechanisms and time course from that observed in age, sex, weight
and BMI matched control subjects. Previous reporting specifically addressing the metabolic
aspects of ALMS are scanty and typically relate to sporadic cases, sometimes not genetically
confirmed, or lacking a control group [6, 13-15]. The cohort described in this study is the
largest ever reported on this topic. Furthermore, the metabolic complications might have a
great impact on management, quality of life and prognosis of patients and elucidation of
their mechanisms that might shed new light on therapy.
We found that ALMS individuals were characterized by a childhood overweight or obesity
that partially normalized as they reached adulthood, with weight and BMI trends differing
by gender. In fact, weight SDS, BMI SDS and fat mass reduction in adults was significant
only in males. This differs from what is reported in general population, where generally
weight and BMI progressively increase with age. Also contrary to the general population,
ALMS is characterized by fat accumulation in subcutaneous instead of visceral regions [15].
In a study of 12 UK ALMS patients, waist circumference and fat mass, but not BMI, were
negatively correlated with age [14]. Furthermore, there was no significant gender difference
in the percentage of body fat although it was suggested that males had higher total fat levels.
The 3-fold increase in the number of subjects included in the present cohort and the wide
age range might explain the different results.
Animal models do not help to clarify this observation, since in the three mouse models of
ALMS [16-18] aging was associated with progressive increase of body weight and fat mass.
Furthermore, in the Alms1 gene-trapped mouse model,, Alms1GT/GT the majority of adipose
tissue was found in the subcutaneous and reproductive regions with adiposity indices higher
in females (3-fold) than males (2-fold) in comparison to controls and only males become
hyperglycemic [16].
The pathogenesis of obesity in ALMS patients is still unknown. Hyperphagia could be
responsible for the progressive weight gain and for the secondary metabolic complications.
At present it has been reported only anecdotally in some subjects, particularly in childhood,
but one report documents a normalizing of BMI and prevention of hyperinsulinemia in a
year old child on caloric restriction [7]. In the mouse model, fat aussie (foz/foz),
hyperphagia was observed before they started to gain weight [17]. It is therefore possible
that with ageing, the food-intake behavior could change or modification of ciliary
hypothalamic function might occur.
In the metabolic aspects of the subset of the Italian ALMS patients, we have noted a
differences glycaemic balance with ageing. In adults, the prevalence of T2DM was 22%,
and when the other metabolic complications (IGT, IFG) are considered, the percentage of
glucose metabolism derangement in adults was 67%. Very young subjects (< 7 y) in spite of
overweight or obesity showed normal insulin resistance insulin sensitivity and beta-cell
function in comparison to BMI matched controls. On the contrary, in age groups >7 y
insulin-resistance (HOMA-IR) was consistently significantly elevated, whereas insulin
sensitivity (ISI) was reduced in comparison to controls only in older patients (>18 y). Both
these parameters were unmodified across age groups. Our results provide evidence for a
mechanism of insulin-resistance independent of body weight. In the general population, fat
mass reduction results in a reduction of liver steatosis and enhanced glucose tolerance.
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However, in lipodystrophies fat mass reduction leads to a decrease rather than an increase in
systemic insulin sensitivity [19]. Insulin-resistance might be accompanied by rising free
fatty acids levels which indirectely favor triglyceride infiltration of the liver and pancreas
although insulin driven lipogenesis can also make a significant contribution to fatty liver. In
this study, ALMS patients showed an elevation of their lipid profile and hepatic enzymes
across age groups. Free fatty acids remain uninvestigated in ALMS, but Paisey et al
described a marked hypertriglyceridaemia independent from insulin levels or metabolic
profile [6]. The β-cell function determined by the HOMA %βcell and the Insulinogenic
Index, was augmented in ALMS patients compared to age matched controls, but was
reduced in patients > 18y, with those under 18y having a significantly higher β-cell
secretion. The higher β-cell secretion could be interpreted as a compensatory mechanism
made by pancreatic β-cells in order to temporarily maintain glucose homeostasis in the
presence of a marked insulin-resistance. Also in the Alms1GT/GT and foz/foz, mouse
models, hyperinsulinemia develops early and pancreatic islets show beta cell proliferation,
thus suggesting that both insulin-resistance and increased insulin secretion might contribute
to glucose intolerance. Development of diabetes could therefore, result from the metabolic
effect of “β-cell exhaustion”. The primary cause of the insulin- resistance is most likely to
be due to the effects of ALMS1 mutations on ciliary function and distinct from simple
obesity.
Finally, since it has been described the presence of systemic fibrosis in biopsies and post-
mortem investigations [1,5], it can be hypothesized that fibrosis occurring at the pancreatic
level could compromise β-cell function resulting in secondary diabetes. Insulin secretion
could in this situation be concomitantly decreased due to reduction in glucagon reserve. This
has not been studied in Alström syndrome.
Strengths of the current study include the relatively large cohort of ALMS patients, their
accurate genetic characterization, the comparison with an age, BMI, and weight matched
population, as well as the application of validated measures of both insulin resistance and
beta-cell dysfunction widely used in large clinical studies. Limitations include the cross-
sectional design, and the use of surrogate rather than direct measures of insulin resistance
and beta cell function. However, direct measures (such as clamp studies) would be difficult
to implement given their cost, invasiveness and time requirement, which might be
particularly burdensome especially in younger subjects.
To summarize, we can affirm that both insulin-resistance and β-cell failure are the two
determinant factors responsible for the development of glucose metabolism alterations in
Alström patients. In ALMS the progression from the early onset obesity towards the
impaired fasting glucose or IGT and overt diabetes is mostly due to a progressive failure of
β-cell insulin secretion without any further worsening of insulin resistance with age. It is
atypical and noteworthy to find these metabolic alterations even in the presence of weight
reduction, which differs from the general population and is much more similar to
lipodystrophy..
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Figure 1. Glucose and insulin responses during OGTT according to age groups in ALMS and
controls
(a) glucose response < 7 y, (b) insulin response < 7 y, (c) glucose response 7-18 y, (d)
insulin response 7-18 y, (e) glucose response > 18 y, (f) insulin response > 18 y. Alström
subjects are indicated by white circles and white bars, control subjects by black circles and
black bars. AUC, area under curves. *P < 0,05; **P < 0.01
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Figure 2. Comparison of HOMA-IR, HOMA% β-cell, Insulin Sensitivity Index and
Insulinogenic Index in ALMS patients and controls
Alström subjects are indicated by white bars, control subjects by black bars. Values of
HOMA-IR (a), HOMA-βcell (b), Insulin Sensitivity Index (c) and Insulin ogenic Index (d)
are reported as median ±SEM. * P< 0,05); ** P< 0,01
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Figure 3. Hepatic and lipid profile in ALMS patients
Hepatic (a) and lipid (b) profile in ALMS patients considered by three different classes of
age: <7 y (white bars), 7-18 y (dashed bars), > 18 y (black bars). Values are expressed as
mean ± SEM. The dotted lines (a) indicate the upper limit of normal values of patients < 7 y,
the dashed lines (a, b) indicate the upper limit for normal values of patients > 7 y. AST,
aspartate aminotransferase; ALT, alanine aminotransferase; gGT, gamma glutamyl
transpeptidase; TOT-C, total cholesterol; HDL-C, high density lipoprotein-cholesterol; TG,
triglycerides; LDL-C, low density lipoprotein-cholesterol.
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Table 2
Number of observations for metabolic investigations
Patient # ≤ 6 yrs (3-6 y) 7-18 yrs (8-18 y) >18 yrs (19-51 y)
1 X
2 X
3 X
4 X
5 X
6 X
7 XX X
8 XXX
9 X
10 X X
11 X XX
12 X X
13 X
14 X
15 XXX
tot patients 5 5 9
tot observations 5 6 14
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